CTRI/2019/03/018143已完成3 期
A Multicentric, Randomized, Open Label Clinical Trial to Evaluate Efficacy and Safety of Tapentadol Nasal Spray in Comparison to Tramadol Immediate Release Capsule and Intravenous Injection in Patients with Post-Operative Moderate to Severe Pain
Torrent Pharmaceutical Ltd0 个研究点目标入组 294 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 294
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female subjects of 18-65 years of age, both inclusive.
- •2. Patient is fit for surgery under general anaesthesia or regional anaesthesia
- •3. Patients having physical status of I-II according to American Society of Anaesthesiologists (ASA) classification.
- •4. After weaning of anaesthesia post-surgery, patients having pain intensity score >= 4 on an 11-point (0 to 10) Numeric
- •Pain Rating Scale (NPRS).
- •5. Patient willing to remain hospitalized for a minimum of 5 days post-surgery.
- •6. Patient willing to give written informed consent to participate in the study before undergoing surgical intervention.
排除标准
- •1. Patients with a history of hypersensitivity to Tapentadol or Tramadol.
- •2. History of active or suspected gastrointestinal ulcers or bleeding or motility disorder within the past 6 months prior to screening.
- •3. Patient who will undergo either laparoscopic surgeries (eg. laparoscopic cholecystectomy, laparoscopic appendectomy) or cardiothoracic surgeries (eg. heart bypass surgery, open esophagectomy) or cancer surgeries (eg. mastectomy).
- •4. Patients who have taken any medication by intranasal route within the past 72 hours prior to randomization.
- •5. Patients who have received analgesic postoperatively prior to
- •randomization.
- •6. Patients with chronic use of any opioids for any disease within the last 28 days prior to screening.
- •7. Patients currently being treated with tricyclic antidepressants, selective serotonin reuptake inhibitors, selective noradrenaline reuptake inhibitors, anticonvulsants, neuroleptics, triptans, monoamine oxidase inhibitors, steroids or other drugs that has potential to reduce the seizure threshold within the past 4 weeks prior to screening.
- •8. Patients having clinically significant postoperative complications before randomization which may compromise safety of the patient or study outcome as per investigator opinion.
- •9. History of any seizure disorder or epilepsy.
- •10. Patients with history of mild to moderate traumatic brain injury (loss of consciousness >= 30 minutes to 6 hours), stroke or brain neoplasm within past 1-year or severe traumatic brain injury (loss of consciousness >= 6 hours) within past 15
- •years prior to screening.
- •11. Patients with clinically significant ECG abnormalities or QTc >= 450 msec for male or QT >= 470 msec for female at screening.
- •12. Any clinically significant abnormal nasal or respiratory tract conditions i.e., atrophic rhinitis, nasal polyp, upper respiratory tract infection etc. which can interfere with the absorption of the drug.
- •13. History of drug abuse or known active alcohol abuse within past 6 months.
- •14. Patients with liver enzymes (Alanine transaminase, Aspartate transaminase, Alkaline phosphatase) > 2.5X the upper limit of normal value (ULN) or total bilirubin >1.5X of ULN or serum creatinine >1.5X of ULN at screening.
- •15. Patients having respiratory rate less than 12 breaths per minute or greater than 20 breaths per minute at randomization.
- •16. History of active Hepatitis B or Hepatitis C or HIV infection.
- •17. Pregnant or lactating women.
- •18. In the opinion of the investigator, patient is either unable to cooperate or unlikely to adhere with any study procedures.
- •19. Patients who have participated in any other investigational drug trial within the past four weeks prior to screening.
研究者
相似试验
进行中（未招募）
不适用
A multicenter, randomized, open label, clinical trial to evaluate three doses of tipranavir boosted with ritonavir (500 mg/200 mg qd, 250 mg/100 mg bid and 500 mg/100 mg bid) by assessing the steady-state pharmacokinetics and short-term efficacy and safety in HIV-1 positive treatment naïve patients - NDHIV-1 infected antiretroviral treatment-naive patientsMedDRA version: 6.1Level: HLTClassification code 10052740EUCTR2006-005256-33-ITBOEHRINGER ING.84
进行中（未招募）
不适用
A multicenter, randomized, open label, clinical trial to evaluate three doses of tipranavir boosted with ritonavir (500 mg/200 mg qd, 250 mg/100 mg bid and 500 mg/100 mg bid) by assessing the steady-state pharmacokinetics and short-term efficacy and safety in HIV-1 positive treatment naïve patientsThe patients for this study are to be HIV-1 infected antiretroviral treatment-naïve men and women, from 18 to 65 years of age.MedDRA version: 9.1Level: LLTClassification code 10020192Term: HIV-1EUCTR2006-005256-33-DEBoehringer Ingelheim Pharma GmbH & Co. KG84
已完成
不适用
Heart Failure Reversal Treatment for Chronic heart failure patients.CTRI/2015/01/005384Dr Rohit Sane as a Director70
已完成
3 期
A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancerHER-2 positive locally advanced or metastatic breast tumor10006291breast cancerNL-OMON55876Byondis BV25
进行中（未招募）
1 期
A study to compare the efficacy and safety of SYD985 to four standard available treatments in patients with HER2-positive unresectable locally advanced or metastatic breast cancer.breast tumoursMedDRA version: 21.1Level: LLTClassification code 10006317Term: Breast tumour malignantSystem Organ Class: 100000004864EUCTR2017-001994-18-NLByondis BV345